PMID- 27399125
OWN - NLM
STAT- MEDLINE
DCOM- 20170221
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 95
IP  - 27
DP  - 2016 Jul
TI  - Stent thrombosis and adverse cardiovascular outcomes observed between six months 
      and five years with sirolimus-eluting stents and other drug-eluting stents in 
      patients with Type 2 diabetes mellitus complicated by coronary artery disease: A 
      systematic review and meta-analysis.
PG  - e4130
LID - 10.1097/MD.0000000000004130 [doi]
LID - e4130
AB  - This study aimed to compare 6 months to 5 years stent thrombosis (ST) and adverse 
      cardiovascular outcomes associated with sirolimus-eluting stents (SES) and other 
      drug-eluting stents (DES) in patients with type 2 diabetes mellitus 
      (T2DM).Electronic databases were searched for studies comparing SES with other 
      DES in patients with T2DM. Total ST, definite ST, probable ST, and other adverse 
      cardiovascular outcomes reported between 6 months and 5 years were considered as 
      the clinical end points in this study. Odds ratios (ORs) with 95% confidence 
      intervals (CIs) were calculated for categorical variables and the pooled analyses 
      were performed with RevMan 5.3 software.Twenty-nine studies involving a total 
      number of 25,729 patients with diabetes were included in this meta-analysis. SES 
      were not associated with significantly higher total, definite, and probable STs 
      with OR: 0.95, 95% CI: 0.77-1.17, P = 0.62; OR: 0.94, 95% CI: 0.65-1.37, P = 
      0.76; and OR: 1.05, 95% CI: 0.77-1.45, P = 0.74, respectively. SES were also 
      noninferior to the other non-sirolimus eluting drug eluting stents (non-SE DES) 
      in terms of all-cause mortality, cardiac death, myocardial infarction, and stroke 
      with OR: 0.92, 95% CI: 0.82-1.03, P = 0.16; OR: 1.09, 95% CI: 0.88-1.35, P = 
      0.44; OR: 0.92, 95% CI: 0.80-1.06, P = 0.26; and OR: 0.79, 95% CI: 0.49-1.28, P = 
      0.43, respectively. Target vessel revascularization, target lesion 
      revascularization, and major adverse cardiac events were also similarly reported 
      between SES and non-SE DES with OR: 1.04, 95% CI: 0.83-1.31, P = 0.72; OR: 1.25, 
      95% CI: 0.95-1.64, P = 0.11; and OR: 1.06, 95% CI: 0.90-1.25, P = 0.49, 
      respectively.During this particular follow-up period, SES were not associated 
      with any increase in ST among these patients with T2DM. Mortality and other 
      adverse cardiovascular outcomes were also not significantly different between 
      these 2 groups. Hence, SES should be considered neither superior nor inferior to 
      other DES. They are expected to be equally effective and safe to use in patients 
      with T2DM.
FAU - Bundhun, Pravesh Kumar
AU  - Bundhun PK
AD  - Institute of Cardiovascular Diseases, the First Affiliated Hospital Guangxi 
      Medical University, Nanning, Guangxi, PR China.
FAU - Soogund, M Zafooruddin Sani
AU  - Soogund MZS
FAU - Pursun, Manish
AU  - Pursun M
FAU - Chen, Meng-Hua
AU  - Chen MH
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Cardiovascular Diseases/*etiology
MH  - Coronary Artery Disease/*complications/*therapy
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Angiopathies/*complications
MH  - Drug-Eluting Stents/*adverse effects
MH  - Humans
MH  - Sirolimus/*administration & dosage
MH  - Thrombosis/*etiology
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC5058854
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2016/07/12 06:00
MHDA- 2017/02/22 06:00
PMCR- 2016/07/08
CRDT- 2016/07/12 06:00
PHST- 2016/07/12 06:00 [entrez]
PHST- 2016/07/12 06:00 [pubmed]
PHST- 2017/02/22 06:00 [medline]
PHST- 2016/07/08 00:00 [pmc-release]
AID - 00005792-201607050-00069 [pii]
AID - 10.1097/MD.0000000000004130 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2016 Jul;95(27):e4130. doi: 10.1097/MD.0000000000004130.